05/14/2008
Opexa Therapeutics Schedules First Quarter Results Conference Call; May 21, 2008 at 4:00 p.m. Eastern Tim

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA) will host a conference call on Wednesday, May 21st at 4:00 p.m. Eastern Time, to discuss the Company’s first quarter results and clinical development progress.

The call may be accessed either through the call-in number below or through the audio webcast. The dial-in number for the call is: (651) 291-5254.

This call is being webcast and can be accessed through the Investors page on Opexa’s web site at www.opexatherapeutics.com and will be available on the Company’s web site through June 20, 2008.

Additionally, a replay of the call will be available until Wednesday, May 28, 2008 at 11:59 p.m. ET. The call replay can be accessed by calling:

Domestic Number: Access Code: (800) 475-6701
International Number: Access Code: (320) 365-3844
Access code: 921761

About Opexa Therapeutics
Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Permalink: http://www.businesswire.com/news/opexa/20080514006354/en

- - - -